                         SEQUENCE LISTING

<110>  MONOJUL, LLC
 
<120>  HIGH-AFFINITY ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND 
       METHODS OF USE

<130>  MJL-39610-A

<140>  PCT/US2018/037584
<141>  2018-06-14

<150>  62/519,387
<151>  2017-06-14

<160>  25    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  1

Gly Tyr Thr Phe Thr Tyr Tyr Ala 
1               5               


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  2

Lys Tyr Ser Gln Lys Phe Gln 
1               5           


<210>  3
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  3

Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp 
1               5                   10          


<210>  4
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  4

Ser Leu Arg Ser Asn Tyr 
1               5       


<210>  5
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  5

Gly Gln Phe 
1           


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  6

Asp Ser Arg Val Ser Thr Gly Ile His Val Val Phe 
1               5                   10          


<210>  7
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  7

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Tyr Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  8
<211>  229
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  8

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Tyr Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His Thr Cys Pro Pro 
225                 


<210>  9
<211>  467
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  9

Met Gly Trp Ser Trp Ile Leu Leu Phe Leu Leu Ser Val Thr Ala Gly 
1               5                   10                  15      


Val His Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Tyr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu 
    50                  55                  60                  


Glu Trp Met Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser 
65                  70                  75                  80  


Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser 
                85                  90                  95      


Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
    130                 135                 140                 


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
145                 150                 155                 160 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
                165                 170                 175     


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
            180                 185                 190         


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
        195                 200                 205             


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
    210                 215                 220                 


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 
225                 230                 235                 240 


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
                245                 250                 255     


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
            260                 265                 270         


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
        275                 280                 285             


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
    290                 295                 300                 


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
305                 310                 315                 320 


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
                325                 330                 335     


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
            340                 345                 350         


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
        355                 360                 365             


Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 
    370                 375                 380                 


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
385                 390                 395                 400 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
                405                 410                 415     


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
            420                 425                 430         


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
        435                 440                 445             


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
    450                 455                 460                 


Pro Gly Lys 
465         


<210>  10
<211>  1404
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NUCLEIC ACID SEQUENCE ENCODING HEAVY CHAIN FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  10
atgggctgga gctggatcct gctgttcctc ctgagcgtga cagcaggagt gcacagcgag       60

gtgcagctgg tccagtccgg cgctgaggtg aagaaaccag gggcatccgt gaaagtctcc      120

tgcaaagcca gtggctacac cttcacatac tatgccatgc actgggtgag gcaggctcca      180

ggacagcgac tggaatggat gggctggatc aacgccggca acgggaatac taagtactcc      240

cagaaatttc aggggcgggt gactattacc agagacacct cagccagcac agcttatatg      300

gagctgagct ccctgcgaag cgaagataca gcagtctact attgtgccag agacattagt      360

tacggaagct ttgattattg gggacagggc acactggtga ctgtctctag tgctagcacc      420

aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg      480

gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca      540

ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac      600

tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc      660

aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt      720

gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc      780

ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca      840

tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac      900

ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac      960

cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag     1020

tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa     1080

gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag     1140

aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag     1200

tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc     1260

gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg     1320

aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc     1380

ctctccctgt ctccgggtaa atga                                            1404


<210>  11
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  11

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Phe Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Ile His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
            100                 105                 


<210>  12
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  12

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Phe Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Ile His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 
            100                 105                 110         


Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 
        115                 120                 125             


Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 
    130                 135                 140                 


Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 
145                 150                 155                 160 


Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 
                165                 170                 175     


Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 
            180                 185                 190         


Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 
        195                 200                 205             


Ala Pro Thr Glu Cys Ser 
    210                 


<210>  13
<211>  702
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NUCLEIC ACID SEQUENCE ENCODING LIGHT CHAIN FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  13
atgggctgga gctggatcct gctgttcctc ctgagcgtga cagcaggagt gcacagctct       60

tctgaactta ctcaagatcc cgccgtgtcc gtggccctgg gccagaccgt gaggatcacc      120

tgccagggcg actccctgag gtccaactac gccaattggt accagcagaa gcccggccag      180

gcccccgtgc tggtcatcta cggccagttc aacaggccct ccggcatccc cgaccgcttc      240

tccggctcct cctccggcaa caccgcctcc ctgaccatca ccggcgccca ggccgcagac      300

gaggccgact actactgcga ttccagggtg tccaccggca tccacgtggt gttcggcggc      360

ggcaccaagc tgaccgtgct gggccagccc aaggccgccc cctccgtgac cctgttcccc      420

ccctcctccg aggagctgca ggccaacaag gccaccctgg tctgcctgat ctccgacttc      480

taccccggcg ccgtgaccgt ggcctggaag gccgactcct cccccgtgaa ggccggcgtg      540

gagacaacca ccccctccaa gcagtccaac aacaaatacg ccgcctcctc ctacctgtcc      600

ctgacccccg agcagtggaa gtcccacagg tcctactcct gccaagtcac ccacgagggc      660

tccaccgtgg agaagaccgt ggcccccacc gagtgctcct ag                         702


<210>  14
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN COMPLEMENTARY DETERMINING REGION FROM A HUMAN 
       ANTI-HUMAN FR BETA ANTIBODY

<400>  14

Gly Gln Asn 
1           


<210>  15
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  15

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Ile His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
            100                 105                 


<210>  16
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  16

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Ile His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 
            100                 105                 110         


Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 
        115                 120                 125             


Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 
    130                 135                 140                 


Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 
145                 150                 155                 160 


Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 
                165                 170                 175     


Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 
            180                 185                 190         


Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 
        195                 200                 205             


Ala Pro Thr Glu Cys Ser 
    210                 


<210>  17
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  17

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Tyr Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Phe Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  18
<211>  229
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  18

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Tyr Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Phe Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His Thr Cys Pro Pro 
225                 


<210>  19
<211>  467
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HEAVY CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  19

Met Gly Trp Ser Trp Ile Leu Leu Phe Leu Leu Ser Val Thr Ala Gly 
1               5                   10                  15      


Val His Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Tyr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu 
    50                  55                  60                  


Glu Trp Met Gly Trp Ile Asn Ala Gly Asn Gly Phe Thr Lys Tyr Ser 
65                  70                  75                  80  


Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser 
                85                  90                  95      


Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
    130                 135                 140                 


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
145                 150                 155                 160 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
                165                 170                 175     


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
            180                 185                 190         


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
        195                 200                 205             


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
    210                 215                 220                 


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 
225                 230                 235                 240 


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
                245                 250                 255     


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
            260                 265                 270         


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
        275                 280                 285             


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
    290                 295                 300                 


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
305                 310                 315                 320 


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
                325                 330                 335     


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
            340                 345                 350         


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
        355                 360                 365             


Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 
    370                 375                 380                 


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
385                 390                 395                 400 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
                405                 410                 415     


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
            420                 425                 430         


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
        435                 440                 445             


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
    450                 455                 460                 


Pro Gly Lys 
465         


<210>  20
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  20

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Phe Asn Leu Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Ile His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
            100                 105                 


<210>  21
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIGHT CHAIN SEQUENCE FROM A HUMAN ANTI-HUMAN FR BETA ANTIBODY

<400>  21

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Phe Asn Leu Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Ile His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 
            100                 105                 110         


Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 
        115                 120                 125             


Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 
    130                 135                 140                 


Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 
145                 150                 155                 160 


Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 
                165                 170                 175     


Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 
            180                 185                 190         


Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 
        195                 200                 205             


Ala Pro Thr Glu Cys Ser 
    210                 


<210>  22
<211>  255
<212>  PRT
<213>  Homo sapiens

<400>  22

Met Val Trp Lys Trp Met Pro Leu Leu Leu Leu Leu Val Cys Val Ala 
1               5                   10                  15      


Thr Met Cys Ser Ala Gln Asp Arg Thr Asp Leu Leu Asn Val Cys Met 
            20                  25                  30          


Asp Ala Lys His His Lys Thr Lys Pro Gly Pro Glu Asp Lys Leu His 
        35                  40                  45              


Asp Gln Cys Ser Pro Trp Lys Lys Asn Ala Cys Cys Thr Ala Ser Thr 
    50                  55                  60                  


Ser Gln Glu Leu His Lys Asp Thr Ser Arg Leu Tyr Asn Phe Asn Trp 
65                  70                  75                  80  


Asp His Cys Gly Lys Met Glu Pro Ala Cys Lys Arg His Phe Ile Gln 
                85                  90                  95      


Asp Thr Cys Leu Tyr Glu Cys Ser Pro Asn Leu Gly Pro Trp Ile Gln 
            100                 105                 110         


Gln Val Asn Gln Ser Trp Arg Lys Glu Arg Phe Leu Asp Val Pro Leu 
        115                 120                 125             


Cys Lys Glu Asp Cys Gln Arg Trp Trp Glu Asp Cys His Thr Ser His 
    130                 135                 140                 


Thr Cys Lys Ser Asn Trp His Arg Gly Trp Asp Trp Thr Ser Gly Val 
145                 150                 155                 160 


Asn Lys Cys Pro Ala Gly Ala Leu Cys Arg Thr Phe Glu Ser Tyr Phe 
                165                 170                 175     


Pro Thr Pro Ala Ala Leu Cys Glu Gly Leu Trp Ser His Ser Tyr Lys 
            180                 185                 190         


Val Ser Asn Tyr Ser Arg Gly Ser Gly Arg Cys Ile Gln Met Trp Phe 
        195                 200                 205             


Asp Ser Ala Gln Gly Asn Pro Asn Glu Glu Val Ala Arg Phe Tyr Ala 
    210                 215                 220                 


Ala Ala Met His Val Asn Ala Gly Glu Met Leu His Gly Thr Gly Gly 
225                 230                 235                 240 


Leu Leu Leu Ser Leu Ala Leu Met Leu Gln Leu Trp Leu Leu Gly 
                245                 250                 255 


<210>  23
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  N-terminal amino acids from recombinantly produced FR beta

<400>  23

Ala Asp Pro Gly 
1               


<210>  24
<211>  225
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain amino acid seqeunce for antibody binding FR-Beta

<400>  24

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ile Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


Ser 
225 


<210>  25
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain amino acid sequence for antibody binding FR-Beta

<400>  25

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Asn Tyr Ala 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Gln Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Ala 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asp Ser Arg Val Ser Thr Gly Asn His 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 
            100                 105                 110         


Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 
        115                 120                 125             


Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 
    130                 135                 140                 


Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 
145                 150                 155                 160 


Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 
                165                 170                 175     


Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 
            180                 185                 190         


Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 
        195                 200                 205             


Ala Pro Thr Glu Cys Ser 
    210                 


